



**PEER-REVIEW REPORT**

**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 90472

**Title:** PRaG 3.0 therapy—a novel combination therapy of R 8, radiotherapy, PD-1 inhibitor, GM-CSF and IL-2 for HE -positive metastatic pancreatic ductal adenocarcinoma: A case report

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer’s code:** 02914303

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer’s Country/Territory:** Romania

**Author’s Country/Territory:** China

**Manuscript submission date:** 2023-12-06

**Reviewer chosen by:** Jia-Ru Fan

**Reviewer accepted review:** 2023-12-28 17:30

**Reviewer performed review:** 2024-01-02 12:50

**Review time:** 4 Days and 19 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Novelty of this manuscript</b>	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty



<b>Creativity or innovation of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation
<b>Scientific significance of the conclusion in this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**

REVIEW OF MANUSCRIPT ID: 90472 (World Journal of Gastroenterology)

Congratulations for this very interesting and unique case report of a patient responding well to a novel line of combined treatment (RC48, radiotherapy, pD-1 infibitor, GM-CSF and IL-2) for a very aggressive type of cancer, metastatic pancreatic ductal adenocarcinoma. This is my report regarding the submitted paper. 1. Title. The title does reflect properly the content of the manuscript. The type of article is clearly stipulated: clinical case report. 2. Abstract. The abstract reflects very well all aspects of the manuscript, with clear subchapters. 3. Key Words. Well chosen, but I will suggest removing “case report”, since this type of information is visible within the type of article itself. I would suggest “novel” as a possible replacement. 4. Background. The background is constructed according to a case presentation paper. 5. Methods. This section is constructed according to a case presentation paper. The level of detail is



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** office@baishideng.com  
**https://www.wjgnet.com**

consistent with a case report. Also, the provided CARE Checklist adds more clarity to the paper. 6. Results. This section is constructed according to a case presentation paper. The level of detail is consistent with a case report. 7. Discussion. This section is constructed according to a case presentation paper. The level of detail is consistent with a case report. The number of citations is adequate, and the time span is appropriate. However, please add the proper citation references for the following statements: - in LINE 202, regarding the success rate of first line AG chemotherapy. - in LINE 212, regarding the characteristics of durvalumab (PD-L1 inhibitor) during the mentioned phase II trial. 8. Illustrations and tables. All images provided are suitable for publishing. 9. Biostatistics. Not applicable. 10. Units. Yes. All medical information have been reported in SI. 11. References. The list of references is adequate, also the timespan is appropriate. 12. Quality of manuscript organization and presentation. It is fit for publication. 13. Research methods and reporting. The appropriate CARE Checklist (2013) for Case report has been used. 14. Ethics statements. Documents have been provided. 15. Backmatter. The informed consent of the patient has been obtained and presented. 16. Language quality. The English language is consistently good through the entire manuscript. Also, the authors provided a non-native English certificate for professional proofing. Date, 02.01.2024